Skip to main content
. Author manuscript; available in PMC: 2020 Sep 25.
Published in final edited form as: Ann Neurol. 2020 Jul 2;88(3):574–587. doi: 10.1002/ana.25811

Figure 3. Individual patient data for median change in AD CSF biomarker measurements at each time point.

Figure 3.

Spaghetti plot depicts individual-patient trajectories (left panels) and trend lines (right panels) depict mean values for PD (red) and HC (blue) and 95% CI for mean change in biomarker value at each time point using LMM adjusted for age, sex, and the baseline value of the CSF outcome for mean change in measurements for CSF Aβ42 (A) t-tau (B) and p-tau (C) at 6 months, 12 months, 24 months and 36-month time points. Across all time points we found a greater reduction in CSF Aβ42 (mean difference −41.83 pg/ml, SE=18.94, p=0.03) and p-tau (mean difference=−0.38 pg/ml, SE=0.22, p=0.03), in PD compared to HC with a non-significant trend for CSF t-tau (mean difference=−3.7 pg/ml, SE=2.7, p=0.07).